Answers are grounded in this paper and cite their sources.
Acute Lymphoblastic Leukemia (ALL) is a hematological malignancy affecting lymphoid progenitor cells, accounting for 25–30% of pediatric cancer cases. Despite advances in treatment, complications such as Cytokine Release Syndrome (CRS) significantly impact early mortality in pediatric ALL patients, particularly during the initial phases of chemotherapy. This systematic literature review aimed to examine the role of CRS in early mortality and explore potential therapeutic strategies. The study adhered to PRISMA 2020 guidelines, with quality assessment conducted using the Newcastle–Ottawa Scale (NOS). Findings reveal that CRS, driven by excessive cytokines like IL-6, CRP, and ferritin, exacerbates inflammatory responses, leading to multi-organ failure and increased mortality. Biomarker-driven approaches enable early detection and targeted intervention, including the use of IL-6 receptor antagonists such as tocilizumab and corticosteroids, which show promise in mitigating severe inflammation. Addressing chronic inflammation in survivors is equally critical to reducing long-term complications like metabolic syndrome and neurocognitive deficits. This study emphasizes the importance of understanding CRS mechanisms during chemotherapy and tailoring patient-specific strategies to improve survival outcomes. Future research should focus on optimizing biomarker-based therapies and exploring novel interventions to enhance survival rates and quality of life for ALL patients and survivors.
No takes yet. Share an insight, caveat, or question.
Fadillah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: